Want to see ICCC full AI Analyst Report?
ICCC Stock Chart & Stats
$6.24
-$0.45(-8.32%)
At close: 4:00 PM EST
$6.24
-$0.45(-8.32%)
Day’s Range― - ―
52-Week Range$4.52 - $11.16
Previous CloseN/A
Volume9.49K
Average Volume (3M)20.75K
Market Cap
$93.09M
Enterprise Value$90.87M
Total Cash (Recent Filing)$6.81M
Total Debt (Recent Filing)$12.78M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding9,046,799
10 Day Avg. Volume22,482
30 Day Avg. Volume20,748
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)2.05
Price to Sales (P/S)2.01
P/FCF Ratio45.32
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue3.04
Enterprise Value/Gross Profit7.13
Enterprise Value/Ebitda38.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationSustained positive operating and free cash flow signals the company can fund operations and reinvest without relying on new debt or equity. Over 2–6 months this improves financial flexibility for capacity spend, commercial expansion, and reduces liquidity risk versus prior negative cash flow periods.
Growing US Market ShareMeaningful share gains in the core U.S. scours biologics category demonstrate competitive advantage and commercial execution. A larger share supports pricing power, repeat demand, and amortization of fixed manufacturing costs, underpinning more durable revenue and margin expansion.
Funded Capacity ExpansionAvailable cash plus a $2.0M settlement earmarked for capacity improvements enables prioritized investments (drying equipment, yield initiatives). This funded expansion addresses chronic availability constraints and supports sustainable volume growth and improved gross margins over the next 6–12 months.
Bears Say
International Revenue WeaknessSharp international declines highlight commercialization and execution gaps outside the U.S. Reliance on domestic demand concentrates revenue risk; durable global expansion will require sustained investment in distribution, regulatory work, and field coverage before contributing materially.
Manufacturing And Execution RiskOperational fragility (contamination risk, backorders, complex plant upgrades) poses a persistent threat to supply continuity and margins. Execution delays or quality issues during the ~12-month expansion could constrain sales, increase costs, and undermine the recent turnaround's durability.
Bottom-line Profitability Not Yet ConsistentAlthough operating results improved, a small TTM net loss and inconsistent prior profitability limit the company’s ability to compound equity and return capital over time. Persistent bottom-line recovery is needed to convert cash generation into sustainable shareholder value.
Immucell News
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $4.52 and its highest was $11.16 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $93.09M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is Aug 19, 2026 which is in 46 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on May 14, 2026. The company reported $0.215 earnings per share for the quarter, beating the consensus estimate of N/A by $0.215.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,046,799 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of $0.215 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.99%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.72%
12-Months-Change
Fundamentals
Return on Equity
-1.88%
Trailing 12-Months
Asset Growth
-3.32%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
ICCC Company Deck
ICCC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a number of meaningful operational and commercial positives including a record $10.4M revenue quarter, strong domestic growth, improved gross margins and net income, significant manufacturing yield gains and market share expansion led by Tri-Shield. Management also highlighted disciplined investments in commercial coverage, international planning, and a $2.0M settlement earmarked for capacity expansion. Key risks remain around international sales weakness, higher operating expenses, and executional manufacturing/capacity challenges (contamination risk and the need for a major processing-plant expansion). Overall, the positives—record revenue, margin and income improvements, visible market-share gains, and capital to invest in capacity—appear to materially outweigh the lowlights in the near term.View all ICCC earnings summariesTechnical Analysis
Medicinova
―
Adicet Bio
―
Werewolf Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
4.08% Insiders
3.95% Mutual Funds
3.42% Other Institutional Investors
85.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---